早产儿视网膜病变玻璃体内贝伐珠单抗较低剂量评估:一项1期剂量研究
该研究为掩蔽、多中心、1期剂量递减研究,2015年5月至2016年9月纳入61例1型早产儿视网膜病变(ROP)早产儿,评估玻璃体内贝伐珠单抗0.25 mg、0.125 mg、0.063 mg和0.031 mg的疗效。主要结局显示各剂量组成功率分别为11/11眼、14/14眼、21/24眼和9/9眼,0.031 mg剂量有效并需进一步研究。
要点
- 0.031 mg贝伐珠单抗在9/9眼中有效,为研究中最低有效剂量。
- 0.25 mg、0.125 mg、0.063 mg组成功眼数分别为11/11、14/14、21/24。
- 作者认为0.031 mg剂量有效并需进一步研究。
核心结论
- 0.031 mg贝伐珠单抗在该1期研究中9/9眼有效,并需进一步研究。
研究设计与样本
- 2015年5月至2016年9月开展的掩蔽、多中心、1期剂量递减研究,纳入61例1型ROP早产儿。
- 每剂量组10至14例婴儿的一只眼接受玻璃体内贝伐珠单抗,剂量依次为0.25 mg、0.125 mg、0.063 mg和0.031 mg。
主要发现
- 61例入选婴儿中58例完成4周结局,平均出生体重709 g,平均胎龄24.9周。
- 0.25 mg组11/11眼成功,0.125 mg组14/14眼成功,0.063 mg组21/24眼成功,0.031 mg组9/9眼成功。
关键数值与推荐
- 成功定义为注射后5天内或更早注射前附加病变或I区3期ROP改善,且4周内无1型ROP复发或需额外治疗的严重新生血管。
- 使用300 µL注射器和5/16英寸、30号固定针头注射稀释的贝伐珠单抗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出0.031 mg剂量有效并需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity. A much lower dose may be effective while reducing systemic risk. OBJECTIVE: To find a dose of intravitreous bevacizumab that was lower than previously used for severe ROP, was effective in this study, and could be tested in future larger studies. DESIGN, SETTING, AND PARTICIPANTS: Between May 2015 and September 2016, 61 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multicenter, phase 1 dose de-escalation study. One eye of 10 to 14 infants received 0.25 mg of intravitreous bevacizumab. If successful, the dose was reduced for the next group of infants (to 0.125 mg, then 0.063 mg, and finally 0.031 mg). Diluted bevacizumab was delivered using 300 µL syringes with 5/16-inch, 30-gauge fixed needles. INTERVENTIONS: Bevacizumab injections at 0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg. MAIN OUTCOMES AND MEASURES: Success was defined as improvement in preinjection plus disease or zone I stage 3 ROP by 5 days after injection or sooner, and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks. RESULTS: Fifty-eight of 61 enrolled infants had 4-week outcomes completed; mean birth weight was 709 g and mean gestational age was 24.9 weeks. Success was achieved in 11 of 11 eyes at 0.25 mg, 14 of 14 eyes at 0.125 mg, 21 of 24 eyes at 0.063 mg, and 9 of 9 eyes at 0.031 mg. CONCLUSIONS AND RELEVANCE: A dose of bevacizumab as low as 0.031 mg was effective in 9 of 9 eyes in this phase 1 study and warrants further investigation. Identifying a lower effective dose of bevacizumab may reduce the risk for neurodevelopmental disability or detrimental effects on other organs.
引用
- Wallace DK, Kraker RT, Freedman SF, et al. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017. PMID: 28448664. doi:10.1001/jamaophthalmol.2017.1055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。